Replies to post #429557 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Complete Abstract Language:

The present disclosure provides compositions and in vitro or ex vivo methods for obtaining an enhanced antigen specific Th1 immune response. The compositions can comprise activation enhanced dendritic cells or T cells produced in vitro. The methods comprise contacting immature dendritic cells with a maturation agent that comprises a dendritic cell maturation agent, interferon y and an inflammation-activating lipid which can produce hyperactivated dendritic cells. The method can further comprise contacting the maturing dendritic cells with a predetermined antigen during maturation. An in vitro or ex vivo method is also provided wherein the hyperactive dendritic cells can be used to induce naive T cell activation, where the activated T cells can be formulated for administration to an individual in need of such treatment. — NWBO patent application, first public April 15, 2021

[ATLnsider]

Very interesting, thanks flipper44.

[Chiugray]

Very interesting thought.

The DC strategy relative to others is becoming clearer and its position to maintain cellular health, whether it is destroying mutated cancer cells or DNA infected virus cells. In the end it is the same to our immune system.

I hope I am not too far off here. Whereas CART-T unnaturally create super soldier T-cells assigned with a single task, DCVax is superior. It gives the General (dendritic cell) the information on who the insurgents are to attack. The benefit here is the General decides how best to fight and win a guerrilla war, knowing they have access to the full breadth of weapons available in the immune system, not just T-cells. There are considerations like collateral damage and ability to identify a constantly adapting enemy. The immune system does that. And not just during the fight, but the benefits of this continue into deploying systemic defense mechanisms afterwards.

[biosectinvestor]

Thank you for the new patent info and Merry Christmas to you Flipper!

Very interesting new patent, in vivi and ex vivo, sounds like it applies to the entire platform.

[Doc logic]

flipper44,

This is the potential for this platform and several of us have been saying this for years. DC therapy has already been being studied in HIV and other diseases and NWBO has the base knowledge of how to properly activate DCs. Most investors have had no clue as to the true potential of this platform. Big pharmas might survive with niche treatments for diseases that have cheaply produced treatments but what NWBO has will lead to cures with immune memory in many diseases and also in vet applications. Best wishes.

[flipper44]

Reprint of new patent application. (To fix cut and paste errors). Application first made public April 15, 2021

Information valid as of: 19 March 2021 (19.03.2021)

Report generated on: 25 December 2021 (25.12.2021)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2021/071977 15 April 2021 (15.04.2021) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/US2020/054621 07 October 2020 (07.10.2020) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
62/912,005 (US) 07 October 2019 (07.10.2019) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61K 39/00 (2006.01)

(71) Applicant(s):
NORTHWEST BIOTHERAPEUTICS, INC. [US/US]; 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US) (for all designated states)
BOSCH, Marnix, Leo [--/--]; Statenplein 6 2582EX 's Gravenhage (NL) (for all designated states)
POWERS, Linda, F. [--/--]; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US) (for all designated states)
BOYNTON, Alton, L. [US/US]; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US) (for all designated states)

(72) Inventor(s):
BOSCH, Marnix, Leo; Statenplein 6 2582EX 's Gravenhage (NL)
POWERS, Linda, F.; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US)
BOYNTON, Alton, L.; c/o Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 (US)

(74) Agent(s):
POOR, Brian, W.; Christensen O'Connor Johnson Kindness PLLC 1201 Third Avenue, Suite 3600 Seattle, WA 98101 (US)

(54) Title (EN): IN VITRO METHODS AND COMPOSITIONS FOR ENHANCING THE ACTIVATION OF DENDRITIC CELLS AND T CELLS, AND FOR INDUCING A TH-1 IMMUNE RESPONSE
(54) Title (FR): PROCÉDÉS ET COMPOSITIONS IN VITRO PERMETTANT D'AMÉLIORER L'ACTIVATION DE CELLULES DENDRITIQUES ET DE CELLULES T, ET PERMETTANT D'INDUIRE UNE RÉPONSE IMMUNITAIRE TH -1

(57) Abstract:
(EN): The present disclosure provides compositions and in vitro or ex vivo methods for obtaining an enhanced antigen specific Th1 immune response. The compositions can comprise activation enhanced dendritic cells or T cells produced in vitro. The methods comprise contacting immature dendritic cells with a maturation agent that comprises a dendritic cell maturation agent, interferon and an inflammation-activating lipid which can produce hyperactivated dendritic cells. The method can further comprise contacting the maturing dendritic cells with a predetermined antigen during maturation. An in vitro or ex vivo method is also provided wherein the hyperactive dendritic cells can be used to induce naive T cell activation, where the activated T cells can be formulated for administration to an individual in need of such treatment.
(FR): La présente divulgation concerne des compositions et des procédés in vitro ou ex vivo permettant d'obtenir une réponse immunitaire Th1 spécifique à un antigène améliorée. Les compositions peuvent comprendre des cellules dendritiques ou des cellules T améliorées par activation produites in vitro. Les procédés consistent à mettre en contact des cellules dendritiques immatures avec un agent de maturation qui comprend un agent de maturation de cellules dendritiques, l'interféron ? et un lipide d'activation d'inflammation qui peut produire des cellules dendritiques hyperactivées. Le procédé peut en outre consister à mettre en contact des cellules dendritiques de maturation avec un antigène prédéterminé pendant la maturation. L'invention concerne également un procédé in vitro ou ex vivo selon lequel les cellules dendritiques hyperactives peuvent être utilisées pour induire l'activation des cellules T naïves, les cellules T activées pouvant être formulées pour être administrées à un individu ayant besoin d'un tel traitement.

International search report:
Received at International Bureau: 18 March 2021 (18.03.2021) [US]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

[eagle8]

Nice Christmas present flipper.
Thanks a lot!

GLTU